دورية أكاديمية
أعرض في EDS

A novel phosphoproteomic landscape evoked in response to type I interferon in the brain and in glial cells.

التفاصيل البيبلوغرافية
العنوان: A novel phosphoproteomic landscape evoked in response to type I interferon in the brain and in glial cells.
المؤلفون: Viengkhou B; School of Life and Environmental Sciences, Charles Perkins Centre and Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, 2006, Australia., White MY; School of Life and Environmental Sciences, School of Medical Sciences, Charles Perkins Centre and Sydney Mass Spectrometry, The University of Sydney, Sydney, NSW, 2006, Australia., Cordwell SJ; School of Life and Environmental Sciences, School of Medical Sciences, Charles Perkins Centre and Sydney Mass Spectrometry, The University of Sydney, Sydney, NSW, 2006, Australia., Campbell IL; School of Life and Environmental Sciences, Charles Perkins Centre and Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, 2006, Australia., Hofer MJ; School of Life and Environmental Sciences, Charles Perkins Centre and Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, 2006, Australia. markus.hofer@sydney.edu.au.
المصدر: Journal of neuroinflammation [J Neuroinflammation] 2021 Oct 16; Vol. 18 (1), pp. 237. Date of Electronic Publication: 2021 Oct 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101222974 Publication Model: Electronic Cited Medium: Internet ISSN: 1742-2094 (Electronic) Linking ISSN: 17422094 NLM ISO Abbreviation: J Neuroinflammation Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2004-
مواضيع طبية MeSH: Brain/*metabolism , Interferon Type I/*pharmacology , Microglia/*metabolism , Phosphopeptides/*metabolism , Proteomics/*methods, Animals ; Brain/drug effects ; Cells, Cultured ; Female ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Microglia/drug effects ; Phosphopeptides/genetics ; Phosphorylation/drug effects ; Phosphorylation/physiology
مستخلص: Background: Type I interferons (IFN-I) are key responders to central nervous system infection and injury and are also increased in common neurodegenerative diseases. Their effects are primarily mediated via transcriptional regulation of several hundred interferon-regulated genes. In addition, IFN-I activate several kinases including members of the MAPK and PI3K families. Yet, how changes to the global protein phosphoproteome contribute to the cellular response to IFN-I is unknown.
Methods: The cerebral phosphoproteome of mice with brain-targeted chronic production of the IFN-I, IFN-α, was obtained. Changes in phosphorylation were analyzed by ontology and pathway analysis and kinase enrichment predictions. These were verified by phenotypic analysis, immunohistochemistry and immunoblots. In addition, primary murine microglia and astrocytes, the brain's primary IFN-I-responding cells, were acutely treated with IFN-α and the global phosphoproteome was similarly analyzed.
Results: We identified widespread protein phosphorylation as a novel mechanism by which IFN-I mediate their effects. In our mouse model for IFN-I-induced neurodegeneration, protein phosphorylation, rather than the proteome, aligned with the clinical hallmarks and pathological outcome, including impaired development, motor dysfunction and seizures. In vitro experiments revealed extensive and rapid IFN-I-induced protein phosphorylation in microglia and astrocytes. Response to acute IFN-I stimulation was independent of gene expression and mediated by a small number of kinase families. The changes in the phosphoproteome affected a diverse range of cellular processes and functional analysis suggested that this response induced an immediate reactive state and prepared cells for subsequent transcriptional responses.
Conclusions: Our studies reveal a hitherto unappreciated role for changes in the protein phosphorylation landscape in cellular responses to IFN-I and thus provide insights for novel diagnostic and therapeutic strategies for neurological diseases caused by IFN-I.
(© 2021. The Author(s).)
References: Cell Metab. 2013 Jun 4;17(6):1009-1020. (PMID: 23684622)
Front Immunol. 2020 Dec 21;11:606874. (PMID: 33408718)
Sci Rep. 2018 Jan 8;8(1):84. (PMID: 29311560)
Nat Biotechnol. 2005 Nov;23(11):1391-8. (PMID: 16273072)
Science. 2014 Oct 3;346(6205):89-93. (PMID: 25147279)
Prog Mol Biol Transl Sci. 2012;106:343-79. (PMID: 22340724)
Biochimie. 2007 Jun-Jul;89(6-7):770-8. (PMID: 17408841)
Rheumatol Int. 2012 Mar;32(3):585-93. (PMID: 21120503)
J Immunol. 1998 Nov 1;161(9):5016-26. (PMID: 9794439)
Nat Immunol. 2013 Sep;14(9):901-7. (PMID: 23872679)
Nat Rev Drug Discov. 2018 May;17(5):353-377. (PMID: 29545548)
Cell. 1995 Jul 28;82(2):241-50. (PMID: 7543024)
Immunol Rev. 2012 Nov;250(1):317-34. (PMID: 23046138)
Mol Syst Biol. 2011 Oct 11;7:539. (PMID: 21988835)
Sci Signal. 2015 Jun 09;8(380):rs6. (PMID: 26060331)
Oncogene. 2000 May 15;19(21):2628-37. (PMID: 10851062)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
Cell. 2018 Aug 9;174(4):1015-1030.e16. (PMID: 30096299)
Curr Opin Pharmacol. 2012 Aug;12(4):464-70. (PMID: 22819198)
Mol Cell Proteomics. 2005 Jun;4(6):721-30. (PMID: 15659558)
Neurobiol Dis. 2019 Apr;124:454-468. (PMID: 30557660)
Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20. (PMID: 25514926)
Blood. 2016 Dec 15;128(24):2824-2833. (PMID: 27663672)
Oncotarget. 2016 Jun 7;7(23):33627-48. (PMID: 27144524)
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11707-12. (PMID: 15289607)
Nat Rev Neurol. 2015 Sep;11(9):515-23. (PMID: 26303851)
PLoS One. 2013;8(3):e57022. (PMID: 23483893)
Nat Rev Immunol. 2012 Jan 06;12(2):125-35. (PMID: 22222875)
EMBO J. 1999 Oct 15;18(20):5601-8. (PMID: 10523304)
Sci Signal. 2009 Dec 08;2(100):re9. (PMID: 19996458)
Cytokine Growth Factor Rev. 2013 Jun;24(3):257-67. (PMID: 23548179)
Dev Med Child Neurol. 2010 Aug;52(8):725-32. (PMID: 20653736)
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6. (PMID: 23203888)
Curr Opin Immunol. 2015 Feb;32:7-12. (PMID: 25463593)
Cell. 1998 May 29;93(5):827-39. (PMID: 9630226)
Bioinformatics. 2014 Feb 15;30(4):523-30. (PMID: 24336805)
J Proteomics. 2012 Oct 22;75(18):5749-61. (PMID: 22906719)
Mol Cell Proteomics. 2012 Oct;11(10):1070-83. (PMID: 22798277)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Mol Cancer. 2018 Feb 19;17(1):48. (PMID: 29455673)
Sci Data. 2018 Mar 13;5:180036. (PMID: 29533394)
Biochim Biophys Acta. 2005 Sep 30;1745(3):401-10. (PMID: 16054712)
J Virol. 2005 Jul;79(13):8295-302. (PMID: 15956575)
Mol Neurobiol. 2018 Apr;55(4):3451-3476. (PMID: 28502044)
Ann Clin Transl Neurol. 2015 Jul;2(7):774-9. (PMID: 26273690)
J Clin Invest. 2018 Jul 2;128(7):3041-3052. (PMID: 29649002)
PLoS One. 2011;6(7):e21800. (PMID: 21789182)
AJNR Am J Neuroradiol. 2009 Nov;30(10):1971-6. (PMID: 19628626)
Aging Cell. 2016 Aug;15(4):706-15. (PMID: 27095270)
J Proteomics. 2011 Dec 10;75(1):177-91. (PMID: 21722762)
Front Immunol. 2017 Jan 26;8:29. (PMID: 28184222)
Proteomics. 2015 Jan;15(2-3):532-44. (PMID: 25367039)
Semin Arthritis Rheum. 2004 Oct;34(2):501-37. (PMID: 15505768)
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13956-61. (PMID: 10570180)
BMC Bioinformatics. 2012 Nov 19;13:308. (PMID: 23164367)
Brain Res. 1999 Jul 17;835(1):46-61. (PMID: 10448195)
Arthritis Rheum. 1992 Apr;35(4):417-22. (PMID: 1373622)
Mol Cell Biol. 2011 Jun;31(11):2349-63. (PMID: 21444723)
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450. (PMID: 30395289)
Mol Cell Biol. 2009 Sep;29(17):4778-87. (PMID: 19564411)
Cell. 2010 Dec 23;143(7):1174-89. (PMID: 21183079)
Mol Neurobiol. 2018 Feb;55(2):1750-1761. (PMID: 28224476)
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E601-E609. (PMID: 29317535)
J Clin Invest. 2017 Mar 1;127(3):843-856. (PMID: 28134626)
Nucleic Acids Res. 2009 Jan;37(1):1-13. (PMID: 19033363)
Curr Protoc Bioinformatics. 2011 Sep;Chapter 13:Unit 13.15-24. (PMID: 21901740)
Mol Cell Proteomics. 2008 Apr;7(4):645-60. (PMID: 18006492)
Cell. 2006 Nov 3;127(3):635-48. (PMID: 17081983)
Nat Rev Immunol. 2005 May;5(5):375-86. (PMID: 15864272)
Neurobiol Aging. 2014 May;35(5):1012-23. (PMID: 24262201)
J Clin Invest. 2020 Apr 1;130(4):1912-1930. (PMID: 31917687)
Nat Biotechnol. 2015 Sep;33(9):990-5. (PMID: 26280412)
Genome Biol. 2002 Oct 24;3(11):research0062. (PMID: 12429061)
PLoS One. 2012;7(12):e53129. (PMID: 23285258)
Gastroenterology. 2000 Apr;118(4):735-48. (PMID: 10734025)
Cytokine Growth Factor Rev. 2013 Jun;24(3):217-25. (PMID: 23711406)
Nat Rev Immunol. 2015 Jul;15(7):429-40. (PMID: 26052098)
PLoS One. 2007 Aug 01;2(7):e656. (PMID: 17668044)
Glia. 2018 Oct;66(10):2058-2078. (PMID: 30051922)
Ann Rheum Dis. 2015 Oct;74(10):1931-9. (PMID: 24906636)
EMBO J. 2001 Jan 15;20(1-2):91-100. (PMID: 11226159)
فهرسة مساهمة: Keywords: Astrocyte; Cerebral type I interferonopathy; Interferon; Microglia; Neurodegenerative disease; Phosphoproteomics
المشرفين على المادة: 0 (Interferon Type I)
0 (Phosphopeptides)
تواريخ الأحداث: Date Created: 20211017 Date Completed: 20220209 Latest Revision: 20220209
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8520650
DOI: 10.1186/s12974-021-02277-x
PMID: 34656141
قاعدة البيانات: MEDLINE
الوصف
تدمد:1742-2094
DOI:10.1186/s12974-021-02277-x